Evidence map›Paper›PMID 37393983›Full record

ArticleArchives of biochemistry and biophysics2023

The 2.4 Å structure of Zymomonas mobilis pyruvate kinase: Implications for stability and regulation.

Kathleen M Meneely, Jeffrey S McFarlane, Collette L Wright, Kathryn Vela, Liskin Swint-Kruse, Aron W Fenton, Audrey L Lamb

Open access · greenAbstract read
In one paragraph

Article in Archives of biochemistry and biophysics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Rheostatic contributions to protein stability can obscure a position's functional role.Protein science : a publication of the Protein Society · 2024
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kathleen M MeneelyDepartment of Chemistry, University of Texas at San Antonio, San Antonio, TX, 78249, USA.
Jeffrey S McFarlaneDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS, 66045, USA.
Collette L WrightDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS, 66045, USA.
Kathryn VelaDepartment of Chemistry, University of Texas at San Antonio, San Antonio, TX, 78249, USA.
Liskin Swint-KruseDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS, 66160, USA.
Aron W FentonDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS, 66160, USA.
Audrey L LambDepartment of Chemistry, University of Texas at San Antonio, San Antonio, TX, 78249, USA. Electronic address: audrey.lamb@utsa.edu.
The University of Texas at San Antonio · USUniversity of Kansas · USUniversity of Kansas Medical Center · US

Funding

Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Douglas E Wright · 2012 to 2026
$63.0M
X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
TRAINING GRANT IN DYNAMIC ASPECTS OF CHEMICAL BIOLOGYT32GM008545 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LAMB, AUDREY L · 1994 to 2019
$4.9M
Using dynamic network models to quantitatively predict changes in binding affinity/specificity that arise from long-range amino acid substitutionsR01GM147635 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI OZKAN, SEFIKA BANU, SWINT-KRUSE, LISKIN · 2022 to 2025
$1.8M
Towards exome analyses: Surprising outcomes from mutating nonconserved positionsR01GM118589 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI FENTON, ARON W, LAMB, AUDREY L · 2017 to 2020
$1.3M
Novel and essential metallophores from multidrug resistant bacterial pathogensR01GM127655 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI LAMB, AUDREY L · 2018 to 2020
$910k
NIGMS NIH HHS P20 GM103418NIGMS NIH HHS P41 GM103393NIGMS NIH HHS R01 GM118589NIGMS NIH HHS R01 GM127655NIGMS NIH HHS R01 GM147635NIGMS NIH HHS T32 GM008545
6 · The paper itself

Abstract

Human liver pyruvate kinase (hlPYK) catalyzes the final step in glycolysis, the formation of pyruvate (PYR) and ATP from phosphoenolpyruvate (PEP) and ADP. Fructose 1,6-bisphosphate (FBP), a pathway intermediate of glycolysis, serves as an allosteric activator of hlPYK. Zymomonas mobilis pyruvate kinase (ZmPYK) performs the final step of the Entner-Doudoroff pathway, which is similar to glycolysis in that energy is harvested from glucose and pyruvate is generated. The Entner-Doudoroff pathway does not have FBP as a pathway intermediate, and ZmPYK is not allosterically activated. In this work, we solved the 2.4 Å X-ray crystallographic structure of ZmPYK. The protein is dimeric in solution as determined by gel filtration chromatography, but crystallizes as a tetramer. The buried surface area of the ZmPYK tetramerization interface is significantly smaller than that of hlPYK, and yet tetramerization using the standard interfaces from higher organisms provides an accessible low energy crystallization pathway. Interestingly, the ZmPYK structure showed a phosphate ion in the analogous location to the 6-phosphate binding site of FBP in hlPYK. Circular Dichroism (CD) was used to measure melting temperatures of hlPYK and ZmPYK in the absence and presence of substrates and effectors. The only significant difference was an additional phase of small amplitude for the ZmPYK melting curves. We conclude that the phosphate ion plays neither a structural or allosteric role in ZmPYK under the conditions tested. We hypothesize that ZmPYK does not have sufficient protein stability for activity to be tuned by allosteric effectors as described for rheostat positions in the allosteric homologues.

Indexed as

Pyruvate KinaseZymomonasAllosteric RegulationBinding SitesCarbohydrate MetabolismHumansPyruvatesPyruvate KinasePyruvatesAllosterismPyruvate kinase

Identifiers

PMID37393983
PMCPMC11257031
OpenAlexW4382657598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.